GLG1 and acute myeloid leukemia: The AM-ligand interactions harnessed in AML therapy so far include: VLA-4 with VCAM-1, VLA-4 and CD44 and E-selectin, E-selectin ligand-1 and E-selectin, as well as the integrin/CD44 interaction with osteopontin, a glycoprotein of the ECM.